Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

[1]  P. Petrides,et al.  Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany , 1998, European journal of haematology.

[2]  J. Esteve,et al.  The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades , 1998, European journal of haematology.

[3]  E. Wattel,et al.  Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. , 1998, Blood.

[4]  D. Blickstein,et al.  Thrombotic complications in essential thrombocythemia with relatively low platelet counts , 1997, American journal of hematology.

[5]  Y. Najean,et al.  Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. , 1997, Blood.

[6]  R. Fischer,et al.  Prognostic factors in idiopathic (Primary) osteomyelofibrosis , 1997, Cancer.

[7]  J. Michiels.  Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia. , 1997, The Netherlands journal of medicine.

[8]  J. Snowden,et al.  Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases , 1997, British journal of haematology.

[9]  T. Pearson,et al.  Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT , 1997, British journal of haematology.

[10]  J. Esteve,et al.  Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosis , 1997, British journal of haematology.

[11]  M. Le Bousse-Kerdilès,et al.  Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis , 1997, British journal of haematology.

[12]  P. V. van Genderen,et al.  Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin , 1997, British journal of haematology.

[13]  Y. Najean,et al.  Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group. , 1997, Blood.

[14]  A. Schafer,et al.  Microvascular Disturbances, Thrombosis, and Bleeding in Thrombocythemia: Current Concepts and Perspectives , 1997, Seminars in thrombosis and hemostasis.

[15]  R. Silver,et al.  Interferon alfa: effects of long-term treatment for polycythemia vera. , 1997, Seminars in hematology.

[16]  R. Mesa,et al.  Anagrelide as a New Platelet-Lowering Agent in Essential Thrombocythemia: Mechanism of Action, Efficacy, Toxicity, Current Indications , 1997, Seminars in thrombosis and hemostasis.

[17]  R. Marchioli,et al.  European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): A Randomized Trial , 1997, Seminars in thrombosis and hemostasis.

[18]  L. Wasserman,et al.  From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. , 1997, Seminars in hematology.

[19]  P. Koudstaal,et al.  Neurologic and Visual Symptoms in Essential Thrombocythemia: Efficacy of Low-Dose Aspirin , 1997, Seminars in thrombosis and hemostasis.

[20]  J. Michiels,et al.  Erythromelalgia and Vascular Complications in Polycythemia Vera , 1997, Seminars in thrombosis and hemostasis.

[21]  P. V. van Genderen,et al.  Erythromelalgia: A Pathognomonic Microvascular Thrombotic Complication in Essential Thrombocythemia and Polycythemia Vera , 1997, Seminars in thrombosis and hemostasis.

[22]  M. Bangerter,et al.  Aspirin in Essential Thrombocythemia: Status Quo and Quo Vadis , 1997, Seminars in thrombosis and hemostasis.

[23]  E. Juvonen,et al.  Proposal for Revised Diagnostic Criteria of Essential Thrombocythemia and Polycythemia Vera by the Thrombocythemia Vera Study Group , 1997, Seminars in thrombosis and hemostasis.

[24]  M. Le Bousse-Kerdilès,et al.  Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. , 1996, Blood.

[25]  J. Michiels,et al.  The myeloproliferative disorders. An historical appraisal and personal experiences. , 1996, Leukemia & lymphoma.

[26]  A. Georgii,et al.  Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. , 1996, Leukemia & lymphoma.

[27]  T. Pearson,et al.  The diagnostic criteria of polycythaemia rubra vera. , 1996, Leukemia & lymphoma.

[28]  T. Pearson,et al.  Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. , 1996, Leukemia & lymphoma.

[29]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[30]  V. Diehl,et al.  Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. , 1996, Leukemia & lymphoma.

[31]  J. Reilly,et al.  Efficacy of recombinant interferon‐alpha (rIFN‐α) in polycythaemia vera: a study of 17 patients and an analysis of published data , 1996, British journal of haematology.

[32]  T. Barbui,et al.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. , 1995, The New England journal of medicine.

[33]  E. Vellenga,et al.  Long‐term treatment with interferon‐α2b for severe pruritus in patients with polycythaemia vera , 1995 .

[34]  S. Chevillard,et al.  Transforming growth factor‐β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis , 1994, British journal of haematology.

[35]  P. Carli.  Epidemiology of polycythemia vera in Cte d'Or (Burgundy). , 1994, Nouvelle revue francaise d'hematologie.

[36]  B. Swolin,et al.  Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications , 1994, European journal of haematology.

[37]  F. Ferrara,et al.  Recombinant interferon α‐2b in the treatment of polycythemia vera , 1993, American journal of hematology.

[38]  P. Koudstaal,et al.  Transient neurological and ocular manifestations of primary thrombocythemia , 1993 .

[39]  B. Brenner,et al.  High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. , 1992, Leukemia & lymphoma.

[40]  O. Zettervall,et al.  Incidence of polycythemia vera in a defined population , 1992, European journal of haematology.

[41]  M. Simoons,et al.  Thrombocythemia and coronary artery disease. , 1991, American heart journal.

[42]  F. Di Raimondo,et al.  Recombinant interferon alpha in the treatment of polycythemia vera. , 1991, Blood.

[43]  E. Feliú,et al.  Life expectancy of patients with chronic nonleukemic myeloproliferative disorders , 1991, Cancer.

[44]  R. Silver.  A new treatment for polycythemia vera: recombinant interferon alfa. , 1990, Blood.

[45]  R. Fisher,et al.  Leukemic transformation in polycythemia vera: Analysis of risk factors , 1990, American journal of hematology.

[46]  S. Pileri,et al.  Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients , 1990, British journal of haematology.

[47]  T. Barbui,et al.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. Hasselbalch,et al.  Prognostic factors in idiopathic myelofibrosis: A simple scoring system with prognostic significance , 1990, European journal of haematology.

[49]  M. Werner,et al.  Chronic myeloproliferative disorders in bone marrow biopsies. , 1990, Pathology, research and practice.

[50]  V. Diehl,et al.  Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data. , 1989, Acta haematologica.

[51]  V. Diehl,et al.  Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorphometric analysis of bone marrow features in trephine biopsies. , 1988, Analytical and quantitative cytology and histology.

[52]  J. Goldberg,et al.  Long-term management of polycythemia vera with hydroxyurea: a progress report. , 1986, Seminars in hematology.

[53]  J. Goldberg,et al.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[54]  S. Geller,et al.  Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. , 1986, Seminars in hematology.

[55]  J. Steketee,et al.  Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. , 1985, Annals of internal medicine.

[56]  A. Varki,et al.  The Syndrome of Idiopathic Myelofibrosis: A CLINICOPATHOLOGIC REVIEW WITH EMPHASIS ON THE PROGNOSTIC VARIABLES PREDICTING SURVIVAL , 1983, Medicine.

[57]  S. Lewis,et al.  Anaemia in myelofibrosis: its value in prognosis , 1983, British journal of haematology.

[58]  B. Armstrong,et al.  The effect of diagnostic review on the estimated incidence of lymphatic and hematopoietic neoplasms in Western Australia , 1981, Cancer.

[59]  F. Triebel,et al.  Pure erythrocytosis: Reappraisal of a study of 51 cases , 1981, American journal of hematology.

[60]  T. Pearson,et al.  The course and complications of idiopathic erythrocytosis. , 2008, Clinical and laboratory haematology.

[61]  P. Peterson,et al.  The bone marrow in polycythemia vera. , 1979, Pathology annual.

[62]  N. Berlin.  Diagnosis and classification of the polycythemias. , 1975, Seminars in hematology.

[63]  M. Block,et al.  Bone marrow sections in the differential diagnosis of polycythemia. , 1972, Archives of pathology.